Janssen & Pharmacyclics Sign for Anti-cancer Compound

The companies have entered into a worldwide agreement for sharing development and commercialization activities regarding the anti-cancer compound, PCI-32765.

Janssen Biotech has inked a deal with Pharmacyclics, Inc. to jointly develop and market the anti-cancer compound, PCI-32765.

Several Phase I and II studies are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.

The companies have entered into a worldwide 50/50 profit-loss agreement, sharing development and commercialization activities. Janssen has made an upfront payment of $150 million and will make additional payments based on certain development and regulatory milestones.